Structural insights into dual-antagonize mechanism of AB928 on adenosine A2 receptors
暂无分享,去创建一个
Mingyao Liu | Yonghui Wang | Weiqiang Lu | Huaiyu Yang | Yueming Xu | Gaojie Song | Qiong Xie | Qiansen Zhang | Chenyu Zhu | Xinyu Yang | Yuan Weng | Ying Chen
[1] R. Cheng,et al. Crystal structure of adenosine A2A receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction , 2023, Communications chemistry.
[2] C. Drake,et al. Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] B. Huck,et al. Abstract 3499: M1069 as dual A2A/A2B adenosine receptor antagonist counteracts immune-suppressive mechanisms of adenosine and reduces tumor growth in vivo , 2022, Cancer Research.
[4] C. Porta,et al. Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. , 2022, Cancer treatment reviews.
[5] J. Labahn,et al. Single Stabilizing Point Mutation Enables High‐Resolution Co‐Crystal Structures of the Adenosine A2A Receptor with Preladenant Conjugates , 2022, Angewandte Chemie.
[6] B. Schwartz,et al. 257 Combination of adenosine antagonists A2AR (TT-10) and A2BR (TT-4) with checkpoint inhibitors demonstrate anti-tumor activity in CT-26 murine colon tumor allograft model , 2021, Journal for ImmunoTherapy of Cancer.
[7] Vikramdeep Monga,et al. Adenosine receptor antagonists: Recent advances and therapeutic perspective. , 2021, European journal of medicinal chemistry.
[8] G. V. van Westen,et al. Identification of V6.51L as a selectivity hotspot in stereoselective A2B adenosine receptor antagonist recognition , 2021, Scientific Reports.
[9] Yonghui Wang,et al. Adenosine A2A Receptor Antagonists for Cancer Immunotherapy. , 2020, Journal of medicinal chemistry.
[10] E. Shakhnovich,et al. Common activation mechanism of class A GPCRs , 2019, eLife.
[11] K. Hirata,et al. KAMO: towards automated data processing for microcrystals , 2018, Acta crystallographica. Section D, Structural biology.
[12] A. Becker,et al. Abstract 4572: Characterization of the potent and selective A2aR antagonist AB928 for the treatment of cancer , 2017 .
[13] B. L. de Groot,et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.
[14] P. Beavis,et al. Indian breast cancer -The shifting paradigms and finding Indian solutions!! , 2015 .
[15] Sunhwan Jo,et al. CHARMM‐GUI Membrane Builder toward realistic biological membrane simulations , 2014, J. Comput. Chem..
[16] Dahlia R. Weiss,et al. High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks , 2013, In Silico Pharmacology.
[17] Alexander D. MacKerell,et al. Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing , 2012, J. Chem. Inf. Model..
[18] R. Stevens,et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.
[19] M. Congreve,et al. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.
[20] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[21] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[22] R. S. Porter,et al. The Pharmacology of Adenosine , 1990, Pharmacotherapy.
[23] P. Kumari,et al. GloSensor assay for discovery of GPCR-selective ligands. , 2017, Methods in cell biology.
[24] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[25] Vincent B. Chen,et al. Acta Crystallographica Section D Biological , 2001 .
[26] 西田 秀太郎,et al. リンパ球の機能と Adenosine Receptor , 1982 .